Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

TSXV:RP - Post Discussion

View:
Post by Ingiboy on Nov 24, 2023 11:54am

Shiseido

Curious to know what Shiseido is planning to do now that they are not obligated to pay any royalties to Replicel when they move forward with their version of RCH-01 (hijacked from Replicel).

We can only assume their second Trial has been completed as it is now at least 3 years since it started. Were the results compelling enough to take the treatment to market ?  Then the questions is outside of Japan where (or can) they market it ?

Next question is Replicel trying to make a deal with Shiseido to sell them the marketing rights to the rest of the world or is Shiseido going to ignore Replicel and market the treatment wherever they want ?

Lastly, what is Replicel working on if they are not negotiating with Shiseido (above) :
Sell the company outright
Move forward with their own version of the hair treatment in Japan
Submit the Dermal Injector for FDA Approval
Sell the Dermal injector
Take Replicel private

I am sure there are many more options.
Comment by ZeoGak on Nov 24, 2023 2:33pm
FWIW, Shiseido (SSDOY) SP last 5 years:
Comment by ZeoGak on Nov 24, 2023 2:37pm
OOPS, screen shoot failed. Link:  https://www.cnbc.com/quotes/SSDOY?tab=news Scoll and click 5 year on graft
Comment by bluemoons20 on Nov 26, 2023 2:15pm
Not  quite  sure what we are looking at.   Shiseido  has been suffering for many years  and recently  appointed a new person in charge to try to turn things around.  Given their current situation  , if  your point is they may be interested inaquiring  Replical  ,  MAYBE  ,  but  lokely at  rock bottom  prices ...more  
Comment by Ingiboy on Nov 26, 2023 7:16pm
There is no chance the two biggest shareholders Andrew & Jamie will sell their 27,400,000 shares at $.08 - $.09 when their share average I am sure is in the $.15 - $.20 range.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities